medroxyprogesterone (Depo-Provera)
Title: medroxyprogesterone (Depo-Provera)Category: MedicationsCreated: 5/21/1998 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Menopause General)
Source: MedicineNet Menopause General - July 19, 2019 Category: Primary Care Source Type: news
Africa: After ECHO, Let's Find Out Why Women Are Not Using Barrier Methods
[allAfrica] Durban -So, the Evidence for Contraceptive Options and HIV Outcome (ECHO) study has found no significant difference in risk of HIV acquisition among women using one of three most methods of birth of control that are used on the continent - Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera), the Copper IUD and Jadelle implant. The results of the study were announced at the 9th SA Aids Conference in Durban by a panel of doctors, scientists and activists. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - June 18, 2019 Category: Infectious Diseases Source Type: news
HIV Risk Does Not Differ With Three Contraceptive Methods
THURSDAY, June 13, 2019 -- For African women seeking effective contraception, there is no significant difference in HIV incidence with use of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUD), and a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 13, 2019 Category: Pharmaceuticals Source Type: news
The Lancet: First randomised trial finds no substantial difference in risk of acquiring HIV for three different forms of contraception
(The Lancet) A randomised trial of more than 7,800 African women found that a type of contraceptive injection (intramuscular depot medroxyprogesterone acetate -- DMPA-IM) posed no substantially increased risk of HIV acquisition when compared with a copper intrauterine device (IUD) and a levonorgestrel (LNG) implant. The results of this first ever randomised trial in the area, published in The Lancet, counter 30 years of epidemiology research suggesting a potential association between some types of contraceptives and risk of acquiring HIV. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 13, 2019 Category: Infectious Diseases Source Type: news
Birth Control Pills (Oral Contraceptive) vs. Depo-Provera (medroxyprogesterone injection)
Title: Birth Control Pills (Oral Contraceptive) vs. Depo-Provera (medroxyprogesterone injection)Category: MedicationsCreated: 5/20/2019 12:00:00 AMLast Editorial Review: 5/20/2019 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - May 20, 2019 Category: OBGYN Source Type: news
Gender-affirming therapy using medroxyprogesterone acetate has few side affects
According to research published in the Journal of Clinical Endocrinology and Metabolism, the use of Medroxyprogesterone acetate in transgender women significantly reduces testosterone without impacting estradiol levels.Endocrinology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 10, 2019 Category: Endocrinology Source Type: news
Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda
CONCLUSIONSContraceptive self-injection has the potential to increase contraceptive access and use for adolescents in Uganda, and should be considered as a delivery modality in the context of adolescent-friendly contraceptive services. (Source: The Guttmacher Institute)
Source: The Guttmacher Institute - May 18, 2018 Category: International Medicine & Public Health Authors: Guttmacher Source Type: news
Better Continuation Rates When Women Self-inject Depot Medroxyprogesterone Better Continuation Rates When Women Self-inject Depot Medroxyprogesterone
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Teva Announces Reintroduction of Generic Depo-Provera in the United States
JERUSALEM--(BUSINESS WIRE)--Sep. 25, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2017 Category: Pharmaceuticals Source Type: news
Update to CDC ’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection
CDC ’s U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) (first published in 2010 and updated in 2016) provides evidence-based guidance for the safe use of contraceptive methods among U.S. women with certain characteristics or medical conditions (1), and is adapted from global guidanc e from the World Health Organization (WHO) and kept up to date based on continual review of published literature (2). CDC recently evaluated the evidence and the updated WHO guidance on the risk for human immunodeficiency virus (HIV) acquisition among women using hormonal contraception. After carefu l review, CDC adopted th...
Source: CDC HIV/AIDS Prevention - September 21, 2017 Category: Infectious Diseases Source Type: news
Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection
CDC's U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) (first published in 2010 and updated in 2016) provides evidence-based guidance for the safe use of contraceptive methods among U.S. women with certain characteristics or medical conditions (1), and is adapted from global guidance from the World Health Organization (WHO) and kept up to date based on continual review of published literature (2). CDC recently evaluated the evidence and the updated WHO guidance on the risk for human immunodeficiency virus (HIV) acquisition among women using hormonal contraception. After careful review, CDC adopted the upd...
Source: CDC HIV/AIDS Prevention - September 21, 2017 Category: Infectious Diseases Source Type: news
